Oslo Pensjonsforsikring AS Makes New Investment in CVS Health Corporation $CVS

Oslo Pensjonsforsikring AS purchased a new stake in shares of CVS Health Corporation (NYSE:CVS) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 447,471 shares of the pharmacy operator’s stock, valued at approximately $32,137,000. CVS Health makes up approximately 5.0% of Oslo Pensjonsforsikring AS’s investment portfolio, making the stock its 6th biggest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of CVS. TOWER TRUST & INVESTMENT Co lifted its holdings in shares of CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after buying an additional 132 shares during the period. CYBER HORNET ETFs LLC raised its position in CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after acquiring an additional 134 shares in the last quarter. LS Investment Advisors LLC lifted its holdings in CVS Health by 3.9% in the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after acquiring an additional 135 shares during the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in CVS Health by 4.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock valued at $239,000 after acquiring an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC boosted its position in shares of CVS Health by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after purchasing an additional 136 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on CVS shares. Sanford C. Bernstein boosted their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Royal Bank Of Canada raised their target price on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Bank of America upped their price target on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Weiss Ratings upgraded CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. Finally, Mizuho lifted their target price on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.38.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced that common prescription medications for dogs and cats are now available at its roughly 9,000 CVS Pharmacy locations nationwide, expanding the chain’s role beyond human prescriptions and potentially adding a small but incremental revenue stream while increasing store traffic. Pet medications now available at CVS Pharmacy®
• Positive Sentiment: Market commentary highlighted that CVS has been outperforming the broader market, reflecting continued investor confidence in the company’s ongoing operational improvement and turnaround efforts. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Positive Sentiment: Another report echoed the same outperformance theme, noting CVS’s strong trading versus the market and suggesting that investors remain focused on the company’s improving fundamentals. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: A longer-form analysis argued CVS is still in the middle of a meaningful turnaround, with improving margins, declining leverage, and strong cash flow, but it also noted the stock is no longer viewed as a deep bargain after its rally. CVS Health Update: The C- Student Now Pulling Down A B+

Insiders Place Their Bets

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This trade represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last three months. Company insiders own 0.85% of the company’s stock.

CVS Health Trading Up 2.6%

Shares of NYSE CVS opened at $110.40 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a one year low of $58.50 and a one year high of $110.62. The business has a 50-day moving average price of $99.58 and a two-hundred day moving average price of $85.58. The firm has a market capitalization of $140.87 billion, a PE ratio of 48.64, a PEG ratio of 1.05 and a beta of 0.61.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.4%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.